Ann: CEO's address to AGM , page-28

Impressive presso to be sure.

However some observations.

Speaking as a backseat driver, the company and US Military should get a little kick up the bum for not anticipating the pace of recruitment. They knew there was a big ongoing Progesterone trial and that the narrow treatment window would mean some difficulty in recruiting patients.

EFIC and a whole lot more sites should have been on-line on Day 1 of the trial. Its not a good look to be tinkering around with sites and new CROs mid-trial... frankly unprofessional.

Ok, events have moved along, and IV NNZ may end up not being the main gig (with oral NNZ taking over etc).

We have to remember the patent clock keeps a ticking... its stops for no-one. We wont get results for IV NNZ probably until 2014. Off the top o my head the patent expires 2023 (stand to be corrected). Add 2-3 years for Phase III, 1 year for approval, that gives us 5 years protection in the market.... thats assuming no major hold ups occur... 5 yrs protection in market aint flash however we can get up to 5 years patent extension under the Patent Restoration Program for time spent in clinical trials.... but we have to rely on the good graces of the USPTO/FDA.

All up, exciting stuff but the somewhat self-imposed slow recruitment pace in the Intrepid trial and the xenograft SNAFU are cautionary red flags...

Go NEU...

P.S. They dont want to tell us the actual current recruitment number so it must be bad lol...